-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

BRIEF-Nabriva Therapeutics Provides Corporate Update

Reuters · 01/06/2023 07:11
BRIEF-Nabriva Therapeutics Provides Corporate Update

- Nabriva Therapeutics PLC NBRV.O:

  • NABRIVA THERAPEUTICS PROVIDES CORPORATE UPDATE

  • NABRIVA THERAPEUTICS PLC - COMPANY TO FOCUS ON PRESERVING CASH TO FUND ORDERLY WIND DOWN OF OPERATIONS

  • NABRIVA THERAPEUTICS PLC - COMPANY TO CONTINUE WORK WITH TORREYA CAPITAL ON ASSET MONETIZATION

  • NABRIVA THERAPEUTICS PLC - COMPANY TO FOCUS ON PRESERVING CASH TO FUND ORDERLY WIND DOWN OF OPERATIONS

  • NABRIVA THERAPEUTICS PLC - PLANS TO TERMINATE ALL EMPLOYEES, INCLUDING OFFICERS OF COMPANY, NOT DEEMED NECESSARY TO EXECUTE AN ORDERLY WIND-DOWN OF CO

  • NABRIVA THERAPEUTICS PLC - ESTIMATES THAT IT WILL INCUR ABOUT $6.0 MILLION FOR SEVERANCE AND OTHER EMPLOYEE TERMINATION-RELATED COSTS IN Q1 OF 2023

  • NABRIVA THERAPEUTICS PLC - TERMINATED ITS AGREEMENT WITH AMPLITY HEALTH, CONTRACT SALES ORGANIZATION RESPONSIBLE FOR PROMOTING SIVEXTRO AND XENLETA

  • NABRIVA THERAPEUTICS PLC - EXPECTS TO TRANSITION RESPONSIBILITY FOR PROMOTION AND DISTRIBUTION OF SIVEXTRO BACK TO MERCK & CO. INC.

  • NABRIVA THERAPEUTICS PLC - BOARD OF DIRECTORS CONTINUES TO EVALUATE ALTERNATIVES TO MAXIMIZE SHAREHOLDER VALUE

  • NABRIVA THERAPEUTICS - REPAID $4.5 MILLION TO HERCULES CAPITAL, INCLUDING PRINCIPAL, ACCRUED & UNPAID INTEREST, FEES & OTHER EXPENSES, UNDER LOAN DEAL

Source text for Eikon: ID:

Further company coverage: NBRV.O


((Reuters.Briefs@thomsonreuters.com;))